FIELD: chemistry.
SUBSTANCE: invention relates to a method of manufacturing crystalline form of chloride (2R, S)-, (2S)- or (2R)-DOTAP (N, N, N-trimethyl-2,3-bis [[(9Z) -1-oxo -9-octadecenyl] oxy]-1-propanamide chloride). The process comprises crystallization chloride (2R, S)-, (2S)- or (2R)-DOTAP of one or more aprotic solvents, wherein the crystallisation takes place by cooling slowly from 35°C to -12°C for constituting 12 hours, or by slowly cooling from a temperature lower than the time period 35°. C over a period of time ranging from 10 to 50 parts crystalline chloride (2R, S)-DOTAP has one of the following characteristics: the values 2 theta, including at least the values constituting 12.6, 19.5, 20.2, 21.5 and 25.2; or 2 theta values, comprising at least the values of 6.5, 12.6, 13.4, 19.5, 20.2, 21.5, 25.2 and 29.8; or an X-ray powder diffraction, the diffraction pattern corresponding to FIG. 1. Crystalline chloride (2S)-DOTAP has one of the following characteristics: the values 2 theta, including at least the values constituting 12.8, 19.5, 19.8, 20.2 and 21.6; 2 theta values, comprising at least the values of 6.5, 12.8, 19.5, 19.8, 20.2, 20.7, 21.6 and 25.3; or an X-ray powder diffraction, the diffraction pattern corresponding to FIG. 2. Crystalline chloride (2S)-DOTAP has one of the following characteristics: the values 2 theta, including at least the values constituting 12.8, 19.5, 19.8, 20.2 and 21.6; 2 theta values, comprising at least the values of 6.5, 12.8, 19.5, 19.8, 20.2, 20.7, 21.6 and 25.3; or an X-ray powder diffraction, the diffraction pattern corresponding to FIG. 3. X-ray powder diffractometry was carried out using Cu as a radiation source.
EFFECT: proposed method allows to obtain crystalline forms of chloride with improved stability and purity.
8 cl, 12 dwg, 5 tbl, 5 ex
Title | Year | Author | Number |
---|---|---|---|
STABLE CRYSTALLINE CHLORIDE MODIFICATIONS DOTAP | 2005 |
|
RU2463291C2 |
SOLID FORMS OF PLADIENOLIDE PYRIDINE COMPOUNDS AND METHODS FOR USE THEREOF | 2016 |
|
RU2743349C2 |
NOVEL CRYSTALLINE FORMS OF N-[-2[[(2,3-DIFLUOROPHENYL)METHYL]THIO]-6-{[(1R,2S)-2,3-DIHYDROXY-1-METHYLPROPYL]OXY}-4-PYRIMIDINYL]-1-AZATIDINE-SULPHONAMIDE | 2011 |
|
RU2548044C2 |
SUBSTITUTED DERIVATIVES OF BISPHENYL ESTER OF BUTYRIC ACID AS NEP INHIBITORS | 2019 |
|
RU2784522C2 |
CHROMENONE COMPOUNDS AS PI3-KINASE INHIBITORS FOR TREATING CANCER | 2012 |
|
RU2598028C2 |
METHOD FOR PREPARATION OF THE COMPOUND 2,2-DIFLUORO-N-((1R,2S)-3-FLUORO-1-HYDROXY-1-(4-(6-(S-METHYLSULFONIMIDOYL)PYRIDINE-3-YL)PHENYL)PROPANE-2-YL)ACETAMIDE | 2019 |
|
RU2765144C1 |
SALTS AND CRYSTALLINE FORMS | 2014 |
|
RU2654855C2 |
CRYSTALLINE MODIFICATIONS OF HYDROCHLORIDE (-)-(1R, 2R)-3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYLPROPYL)PHENOL | 2005 |
|
RU2423345C2 |
POLYMORPHIC AND PSEUDOPOLYMORPHIC FORMS OF PHARMACEUTICAL COMPOUND | 2010 |
|
RU2575173C2 |
METHOD OF SYNTHESIS OF TRIAZOLES, ULTIMATE AND INTERMEDIATE COMPOUNDS OF METHOD | 1996 |
|
RU2156760C2 |
Authors
Dates
2017-08-07—Published
2012-05-02—Filed